Market LIVE
Published markets; coverage varies by country
Product profile · United States

EXALGO

 ·  Patent Litigation & Settlement History ↓

IngredientHYDROMORPHONE HYDROCHLORIDE
Application typeNDA
Application021217
Product003
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength16MG
Approval date2010-03-01
Marketing statusDiscontinued
Status event—
ApplicantSPECGX LLC
Product source

Current GenericRadar decision

Year—
SelectionDISCONTINUED
ReviewFINAL_CHECKING
Anchor typeTERMINAL_MARKETING_STATUS
Anchor date—
Patent anchor—
Exclusivity anchor2013-03-01
Protection date2014-07-07
First Final ANDA—
Status event—

FDA_DISCONTINUED_MARKETING_STATUS. Actual discontinuation date/year not established; do not substitute approval or review date. Store underlying canonical rights separately.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US57027252014-07-07DP/U U-1043NNDP
Product formulation, delivery, excipient, release or preparation claims; no broad independent active-compound claim established. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.
———
US59141312014-07-07DP/U U-1043NNDP
Product formulation, delivery, excipient, release or preparation claims; no broad independent active-compound claim established. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NDF2010-03-012013-03-01Original new dosage form, new combination or exact new product approval; covers its approved formulation/use scope at this original approval.YY2013-03-01Source

2026-10-12 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_2011_2026_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (4)
TypeDateRoleBasisSource
PATENT2014-07-07FTO_TAILProduct formulation, delivery, excipient, release or preparation claims; no broad independent active-compound claim established. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.Source
PATENT2014-07-07FTO_TAILProduct formulation, delivery, excipient, release or preparation claims; no broad independent active-compound claim established. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.Source
REGULATORY_EXCLUSIVITY2013-03-01SCOPE_CONTEXTOriginal new dosage form, new combination or exact new product approval; covers its approved formulation/use scope at this original approval.Source
REGULATORY_STATUS—TERMINAL_STATUSFDA_DISCONTINUED_MARKETING_STATUS. Actual discontinuation date/year not established; do not substitute approval or review date. Store underlying canonical rights separately.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.